Stockreport

Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference [Yahoo! Finance]

Definium Therapeutics, Inc. - Common Shares  (DFTX) 
PDF for MDD) with Breakthrough Therapy designation; the MDD study (Emerge) is fully enrolled and expected to read out in late Q2 2026, Voyage (first GAD pivotal) in early Q3 [Read more]